Тарзиманова А. И., Фомина И. Г. Роль воспаления в патогенезе фибрилляции предсердий. Кардиоваскулярная терапия и профилактика. 2006;5(7):91-94.
1. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22: 1852-923.
2. Atrial fibrillation as a contributing cause of death and Medicare hositalization-United States, 1999. MMWR Morb Mortal WHy Rep 2003; 52: 128-32.
3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987; 147: 1561-4.
4. Li D., Karen S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
5. Engelmann M.D.M., Svedsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-92.
6. Yue L., Feng J., Gaspo R., et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 815: 12-25.
7. Gronefeld G.C., Hohnloser S.H. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003; 8(2): 107-13.
8. S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrilla tion in human patients. Cardiovasc Res 2002; 54(2): 361-79.
9. Kumagai K., Nakashima H., Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-11.
10. Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
11. Nakamura Y., Nakamura K., Fukushima-Kusano K., et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003; 111: 137-42.
12. Falk R.H. Atrial fibrillation. In book: Girdiac Arrhythmia. Ed. Podnd PJ, Kowey PR. Wffliams&Wilkins. Baltimore 1995; 803-28.
13. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
14. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10.
15. Asselbergs F.W., Diercks G.F., van den Berg M.P., et al. C-reactive protein and microalbuminuria are associated with atrial fibrillation. JACC 2003; 41: 99-100.
16. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100-107.
17. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26.
18. Sata N., Hamada N., Horinouchi T., et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004; 45: 441-5.
19. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.
20. Lip G. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-4.
21. Conway D.S.G., Buggins P., Hughes E., Lip G.Y.H. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004; 93: 1368-73.
22. Roldan V., Marin F., Martinez J.G., et al. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005;95:881-2.
23. Madrid A.H., Peng J., Zamora J., et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. PACE 2004; 27: 1405-10.
24. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibril lation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.
25. Nakashima H., Kumagai K., Urata H., et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-7.
26. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000; 101: 207-13.
27. Sacks F.M. High-intensity statin treatment for coronary heart disease. JAMA 2004; 291: 1132-4.
28. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2000; 291: 1071-80.
29. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
30. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-83.
